Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04143217 · ClinicalTrials.gov registry record · Phase 3
Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
A Phase 3 study, sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 159
- Enrollment target
NCT04143217 is a Phase 3 study that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 159 participants.
The verdict
NCT04143217, a Phase 3 study, has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 159 participants
- Enrollment target
Study Summary
Open label, flexible dose, long-term multicenter study of safety and efficacy of SPN-812 in adult ADHD patients
Interventions
- DRUG SPN-812
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2020-01-23 |
| Est. Completion | 2022-12-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04143217
The ClinicalTrials.gov registry entry for NCT04143217 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SPN-812 is the first listed.
NCT04143217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04143217 about?
NCT04143217 is a clinical study titled "Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD". Open label, flexible dose, long-term multicenter study of safety and efficacy of SPN-812 in adult ADHD patients
What is the current status of trial NCT04143217?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 159 participants. The study started on 2020-01-23. Estimated completion is 2022-12-14.
What interventions are being tested in trial NCT04143217?
The interventions under investigation include: SPN-812 (DRUG).
Who is sponsoring clinical trial NCT04143217?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.